FINWIRES · TerminalLIVE
FINWIRES

$QDEL

8 stories mentioning QDELUpdated 30d ago

Every FINWIRES story that references QDEL, newest first.

Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index up 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) gaining 0.2%.The iShares Biotechnology ETF (IBB) rose 0.9%.In corporate news, Zymeworks (ZYME) has agreed to buy Theravance Biopharma (TBPH) for $17 per share in a roughly $929 million deal, the companies said in separate statements. Zymeworks shares were down 0.6%, and Theravance fell 3.2%.Abbott Laboratories (ABT) shares were down 1.3%. The Wall Street Journal reported Sunday the company will not face criminal charges after the US Department of Justice closed a years-long investigation into its baby formula operations.QuidelOrtho (QDEL) shares surged 34%. The company is weighing the sale of its point-of-care testing business behind rapid COVID-19 antigen tests for about $1.5 billion, the Financial Times reported Saturday.Alkermes (ALKS) stock has been re-rated following a recent orexin-peer takeout, but upcoming orexin updates risk eroding newly ascribed orexin-related value, BofA Securities said in a note Monday. BofA downgraded Alkermes to underperform from neutral with a price target of $38. Shares were down 4.7%.

$ABT$ALKS$QDEL$TBPH$ZYME
Sectors

Sector Update: Healthcare Stocks Softer in Afternoon Trading

Healthcare stocks were lower Monday afternoon, with the NYSE Healthcare Index decreasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.2%.The iShares Biotechnology ETF (IBB) rose 0.4%.In corporate news, Abbott Laboratories (ABT) shares were down 0.6%. The Wall Street Journal reported Sunday the company will not face criminal charges after the US Department of Justice closed a years-long investigation into its baby formula operations.Zymeworks (ZYME) has agreed to buy Theravance Biopharma (TBPH) for $17 per share in a roughly $929 million deal, the companies said in separate statements. Zymeworks shares were down 1%, and Theravance fell 2.3%.QuidelOrtho (QDEL) shares surged 34%. The company is weighing the sale of its point-of-care testing business behind rapid COVID-19 antigen tests for about $1.5 billion, the Financial Times reported Saturday.

$ABT$QDEL$TBPH$ZYME
Wire

Market Chatter: QuidelOrtho Weighs Sale of Point-of-Care Testing Business

QuidelOrtho (QDEL) is weighing the sale of its point-of-care testing business behind rapid COVID-19 antigen tests for about $1.5 billion, the Financial Times reported Saturday, citing people familiar with a matter.The company is evaluating bids from private equity companies including Advent International, while other potential suitors like SK Capital Partners and Archimed have also expressed interest, sources told the media outlet.QuidelOrtho did not immediately respond to a request for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $18.58, Change: $+4.79, Percent Change: +34.74%

$QDEL
Wire

QuidelOrtho Appoints Micah Young Chief Financial Officer

QuidelOrtho (QDEL) said Tuesday it appointed Micah Young as chief financial officer, effective July 6, while outgoing finance chief Joseph Busky will continue to work in an advisory capacity.Young most recently served as executive vice president and chief financial officer at Masimo, the company said.Shares of the company were down 3.3% in Tuesday premarket trading.

$QDEL
Research

Jefferies Downgrades QuidelOrtho to Hold From Buy, Adjusts Price Target to $12.50 From $35

QuidelOrtho (QDEL) has an average rating of hold and mean price target of $18.10, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$QDEL
Sectors

Sector Update: Health Care Stocks Decline Late Afternoon

Health care stocks were softer late Thursday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.7%.The iShares Biotechnology ETF (IBB) dropped 1.3%.In corporate news, Abbott Laboratories (ABT) lowered its full-year earnings outlook on Thursday to reflect the acquisition of cancer diagnostics company Exact Sciences, while the healthcare firm reported Q1 results above market estimates. Its shares fell past 5%.Gilead Sciences (GILD) could beat Q1 consensus estimates, but weaker-than-expected persistence rates for Yeztugo point to a potential risk to long-term peak sales for the HIV pre-exposure prophylaxis drug, RBC Capital Markets said in a note. Gilead shares were down 0.8%.QuidelOrtho (QDEL) shares tumbled 28%. The company said late Wednesday it expects preliminary unaudited revenue of $615 million to $620 million for Q1. Analysts polled by FactSet expect $677.8 million.Hims & Hers Health (HIMS) shares jumped past 12% after a senior US health official signaled plans to ease restrictions on certain peptides.

$ABT$GILD$HIMS$QDEL
Sectors

Sector Update: Health Care Stocks Slide in Afternoon Trading

Health care stocks declined Thursday afternoon, with the NYSE Health Care Index decreasing 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 1%.The iShares Biotechnology ETF (IBB) dropped 1.2%.In corporate news, Abbott Laboratories (ABT) lowered its full-year earnings outlook on Thursday to reflect the acquisition of cancer diagnostics company Exact Sciences, while the healthcare firm reported Q1 results above market estimates. Its shares fell past 6%.QuidelOrtho (QDEL) shares tumbled 31%. The company said late Wednesday it expects preliminary unaudited revenue of $615 million to $620 million for Q1. Analysts polled by FactSet expect $677.8 million.Hims & Hers Health (HIMS) shares rose past 7% after a senior US health official signaled plans to ease restrictions on certain peptides.Organon (OGN) is a potential acquisition target by India's Sun Pharmaceutical Industries, Germany's Grunenthal, and private equity firms, Bloomberg reported. Organon shares added 0.7%.

$ABT$HIMS$OGN$QDEL
Wire

Top Midday Decliners

QuidelOrtho (QDEL) shares slumped 32% amid heavy trading after the company set out late Wednesday expectations for preliminary unaudited revenue below market expectations for Q1.Intraday trading volume surged to over 8.5 million shares from a daily average of about 1.6 million.MIND Technology (MIND) reported late Wednesday a fiscal Q4 loss and a year-over-year decline in revenue.Shares slumped 27% as intraday trading volume climbed to more than 895,000 from a daily average of about 153,000.Allbirds (BIRD) fell by 28% after midday, swinging from a 582% surge at Wednesday's close. The company said Wednesday it has executed a definitive agreement with an institutional investor for a $50 million convertible financing facility that will enable a pivot in its business to artificial intelligence compute infrastructure.More than 25.8 million shares of the company traded intraday compared with a daily average of about 4.9 million.Price: $11.91, Change: $-5.58, Percent Change: -31.90%

$BIRD$MIND$QDEL

Track with the FINWIRES app suite

FolioX
FolioX
Track QDEL in your portfolio
WheelAI
WheelAI
Analyze QDEL options with the wheel strategy
StockInsider
StockInsider
See market sentiment on QDEL